JP2024514362A - 慢性疼痛の処置のための経皮医薬製剤 - Google Patents

慢性疼痛の処置のための経皮医薬製剤 Download PDF

Info

Publication number
JP2024514362A
JP2024514362A JP2023564654A JP2023564654A JP2024514362A JP 2024514362 A JP2024514362 A JP 2024514362A JP 2023564654 A JP2023564654 A JP 2023564654A JP 2023564654 A JP2023564654 A JP 2023564654A JP 2024514362 A JP2024514362 A JP 2024514362A
Authority
JP
Japan
Prior art keywords
transdermal
pain
pharmaceutical composition
once
forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514362A5 (cg-RX-API-DMAC7.html
Inventor
エム. プラコヤニス、フォティオス
ラザー、タマンナ
Original Assignee
パイク セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パイク セラピューティクス インコーポレイテッド filed Critical パイク セラピューティクス インコーポレイテッド
Publication of JP2024514362A publication Critical patent/JP2024514362A/ja
Publication of JP2024514362A5 publication Critical patent/JP2024514362A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023564654A 2021-04-22 2022-04-21 慢性疼痛の処置のための経皮医薬製剤 Pending JP2024514362A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163177981P 2021-04-22 2021-04-22
US63/177,981 2021-04-22
PCT/IB2022/053730 WO2022224184A1 (en) 2021-04-22 2022-04-21 Transdermal pharmaceutical formulations for the treatment of chronic pain

Publications (2)

Publication Number Publication Date
JP2024514362A true JP2024514362A (ja) 2024-04-01
JP2024514362A5 JP2024514362A5 (cg-RX-API-DMAC7.html) 2025-04-28

Family

ID=83722736

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564654A Pending JP2024514362A (ja) 2021-04-22 2022-04-21 慢性疼痛の処置のための経皮医薬製剤

Country Status (8)

Country Link
US (1) US20220347151A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326252A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024514362A (cg-RX-API-DMAC7.html)
CN (1) CN117545478A (cg-RX-API-DMAC7.html)
AU (1) AU2022260813A1 (cg-RX-API-DMAC7.html)
CA (1) CA3215685A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023012483A (cg-RX-API-DMAC7.html)
WO (1) WO2022224184A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
CN119896633A (zh) * 2025-01-17 2025-04-29 中国人民解放军空军军医大学 一种水凝胶冷敷贴及其制备的冷热敷贴套装和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503206A (ja) * 2009-08-31 2013-01-31 オールトランツ インコーポレイティド マイクロ針を用いた局所及び経皮投与におけるカンナビジオールプロドラッグの使用
US20170071870A1 (en) * 2015-09-14 2017-03-16 Life Tech Global, Llc Transdermal Delivery of Cannabidiol with Other Active Moieties Including Cannabinoids
US20190133994A1 (en) * 2014-04-18 2019-05-09 Mm Technology Holdings, Llc Transdermal Cannabinoid Patch
US20200261387A1 (en) * 2016-11-17 2020-08-20 Cmpd Licensing, Llc Compounded compositions and methods for treating pain

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990026792A (ko) * 1997-09-26 1999-04-15 김윤 디클로페낙 디에틸암모늄염을 함유한 매트릭스형 패취제제
WO2010127033A1 (en) * 2009-04-28 2010-11-04 Alltranz Inc. Formulations of cannabidiol and methods of using the same
MX2018004034A (es) * 2015-09-30 2018-12-19 Edward Hoag George Formulaciones topicas de analgesicos para alivio del dolor fabricacion y uso de los mismos.
US10525093B2 (en) * 2016-11-14 2020-01-07 Farm To Farma, Inc. Cannabinoid formulations and method of making the same
IL292126B2 (en) * 2018-01-12 2025-04-01 Nutrae Llc Cannabinoid formulations are formulated for oral administration
CA3060926A1 (en) * 2018-09-06 2020-03-06 NuVessl, Inc. Method of using cannabinoids encapsulated in phospholipid carriers for transmucosal and transdermal administration
US20200197359A1 (en) * 2018-09-17 2020-06-25 Cody D. Freeze Cannabinoid and Terpene-Infused Topical Cream
CN118831076A (zh) * 2019-03-12 2024-10-25 Epm (Ip)公司 大麻素酸酯组合物及其用途
AU2020301119B2 (en) * 2019-06-28 2026-03-05 Nexzol Pharma, Inc. Transdermal formulations
CN114650809A (zh) * 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12016829B2 (en) * 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12186280B2 (en) * 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12121617B2 (en) * 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
JP2022551730A (ja) * 2019-10-14 2022-12-13 パイク セラピューティクス,インコーポレイテッド カンナビジオールの経皮送達
US20210346310A1 (en) * 2020-04-20 2021-11-11 Pike Therapeutics, Inc. Transdermal and/or topical, pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain
WO2022003623A1 (en) * 2020-07-01 2022-01-06 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations for the treatment of multiple sclerosis
US20220047541A1 (en) * 2020-08-17 2022-02-17 Pike Therapeutics, Inc. Pharmaceutical compositions and methods for treating parkinson's disease
MX2023006561A (es) * 2020-12-03 2023-07-06 Pike Therapeutics Inc Formulaciones farmaceuticas transdermicas que comprenden cbd o thc para el tratamiento del cancer.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503206A (ja) * 2009-08-31 2013-01-31 オールトランツ インコーポレイティド マイクロ針を用いた局所及び経皮投与におけるカンナビジオールプロドラッグの使用
US20190133994A1 (en) * 2014-04-18 2019-05-09 Mm Technology Holdings, Llc Transdermal Cannabinoid Patch
US20170071870A1 (en) * 2015-09-14 2017-03-16 Life Tech Global, Llc Transdermal Delivery of Cannabidiol with Other Active Moieties Including Cannabinoids
US20200261387A1 (en) * 2016-11-17 2020-08-20 Cmpd Licensing, Llc Compounded compositions and methods for treating pain

Also Published As

Publication number Publication date
CN117545478A (zh) 2024-02-09
US20220347151A1 (en) 2022-11-03
CA3215685A1 (en) 2022-10-27
EP4326252A1 (en) 2024-02-28
MX2023012483A (es) 2023-11-03
WO2022224184A1 (en) 2022-10-27
EP4326252A4 (en) 2025-03-12
AU2022260813A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
US20250248948A1 (en) Transdermal and/or Topical, Pharmaceutical Formulations Comprising Cannabidiol and/or Tetrahydrocannabinol for the Treatment of Chronic Pain
US20220047525A1 (en) Transdermal pharmaceutical formulations of nabilone alone and in combination with cannabinoids
US20260076921A1 (en) Transdermal Pharmaceutical Formulations for the Treatment of Multiple Sclerosis
JP7670700B2 (ja) 発作性障害の治療用のカンナビジオール(cbd)を含む経皮医薬組成物
JP2022551730A (ja) カンナビジオールの経皮送達
US20240261235A1 (en) Pharmaceutical Composition And Method For Treating Seizure Disorders
US20220347151A1 (en) Transdermal pharmaceutical formulations for the treatment of chronic pain
JP2024514843A (ja) 発作性疾患を治療するための医薬組成物及び方法
JP2024035209A (ja) 医薬組成物
KR20070059079A (ko) 경피 페로스피론 투여용 의약적 조성물
JP2024055826A (ja) ロキソプロフェン又はその塩、およびサリチル酸類を含有する医薬組成物
US20250049821A1 (en) Pharmaceutical Composition and Method for Treating Seizure Disorders
JP2024513961A (ja) カンナビジオールの経皮送達

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250418

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260804